NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) major shareholder Nap B.V. Forgrowth sold 49,772 shares of NewAmsterdam Pharma stock in a transaction that occurred on Friday, December 20th. The shares were sold at an average price of $25.60, for a total transaction of $1,274,163.20. Following the sale, the insider now owns 10,802,224 shares in the company, valued at approximately $276,536,934.40. The trade was a 0.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Nap B.V. Forgrowth also recently made the following trade(s):
- On Monday, December 23rd, Nap B.V. Forgrowth sold 25,132 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.49, for a total transaction of $640,614.68.
- On Wednesday, December 18th, Nap B.V. Forgrowth sold 100,728 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $26.10, for a total value of $2,629,000.80.
- On Thursday, December 12th, Nap B.V. Forgrowth sold 166,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.39, for a total value of $4,215,019.29.
- On Monday, November 18th, Nap B.V. Forgrowth sold 33,273 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $25.08, for a total value of $834,486.84.
- On Friday, November 15th, Nap B.V. Forgrowth sold 8,530 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $25.02, for a total transaction of $213,420.60.
NewAmsterdam Pharma Price Performance
Shares of NAMS stock traded up $0.28 during mid-day trading on Thursday, hitting $26.23. The stock had a trading volume of 354,642 shares, compared to its average volume of 377,634. NewAmsterdam Pharma has a 12-month low of $10.50 and a 12-month high of $27.29. The firm's 50-day moving average is $21.72 and its two-hundred day moving average is $19.09.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Frazier Life Sciences Management L.P. increased its holdings in shares of NewAmsterdam Pharma by 5.1% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company's stock valued at $213,396,000 after acquiring an additional 628,251 shares during the period. Janus Henderson Group PLC grew its stake in NewAmsterdam Pharma by 51.1% in the third quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company's stock valued at $25,607,000 after purchasing an additional 520,772 shares during the last quarter. Millennium Management LLC raised its holdings in NewAmsterdam Pharma by 23.0% in the second quarter. Millennium Management LLC now owns 1,165,429 shares of the company's stock worth $22,388,000 after purchasing an additional 217,902 shares in the last quarter. Jennison Associates LLC raised its holdings in NewAmsterdam Pharma by 8.9% in the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company's stock worth $16,937,000 after purchasing an additional 83,115 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C lifted its position in shares of NewAmsterdam Pharma by 30.3% during the second quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company's stock valued at $16,698,000 after buying an additional 202,250 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have commented on NAMS shares. Needham & Company LLC reiterated a "buy" rating and set a $36.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, December 5th. Piper Sandler reiterated an "overweight" rating and issued a $37.00 price target on shares of NewAmsterdam Pharma in a research report on Monday, September 23rd. Royal Bank of Canada restated an "outperform" rating and set a $31.00 price objective on shares of NewAmsterdam Pharma in a research report on Thursday, September 5th. Finally, Scotiabank lifted their target price on NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a report on Wednesday, December 11th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $36.20.
View Our Latest Stock Analysis on NAMS
About NewAmsterdam Pharma
(
Get Free Report)
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Featured Stories
Before you consider NewAmsterdam Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NewAmsterdam Pharma wasn't on the list.
While NewAmsterdam Pharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
